| domain | best-supported finding | suggested ontology terms/IDs (only where confident) | evidence type/strength | key citation DOI/PMID or NCT |
|---|---|---|---|---|
| Definition / criteria | PANS is a clinical syndrome defined by abrupt, dramatic onset of OCD or severely restricted food intake, plus at least 2 additional acute neuropsychiatric symptom categories, not better explained by another neurologic/medical disorder. Onset is typically described within 48 hours. | HPO: Obsessive-compulsive behavior; Food refusal / restricted intake; Anxiety; Emotional lability; Irritability; Developmental regression; Decline in school performance; Sensory disturbance; Sleep disturbance; Enuresis/urinary frequency. MAXO: not applicable. | Consensus/guideline and review evidence; moderate for criteria, low for biological specificity because criteria are syndromic and non-pathognomonic (pqac-00000000, pqac-00000003, pqac-00000004) | DOI:10.3389/fimmu.2024.1420663; PMID 25325534; DOI:10.2147/NDT.S362202 |
| Identifiers / nosology | MeSH term is present in ClinicalTrials-derived browse data as “Pediatric acute-onset neuropsychiatric syndrome.” MONDO/OMIM/Orphanet identifiers were not established from available evidence. PANS is not formally recognized as a DSM-5-TR standalone disorder. | MeSH: Pediatric acute-onset neuropsychiatric syndrome; MONDO: not established; OMIM: not established; Orphanet: not established. | Moderate for MeSH presence; low/unknown for cross-ontology mapping in available context (pqac-00000005, pqac-00000018, pqac-00000019, pqac-00000021) | NCT04508530; NCT02889016; NCT04609761 |
| Synonyms / related entities | Related terms include PANDAS (subset linked to streptococcal infection), Childhood Acute Neuropsychiatric Symptoms/CANS, and acute-onset OCD phenotype. PANDAS is considered a subset of PANS rather than a synonym. | No confident ontology IDs beyond MeSH term above. | Consensus/review; moderate (pqac-00000000, pqac-00000002, pqac-00000022) | DOI:10.3389/fimmu.2024.1420663; NCT02190292 |
| Core phenotypes | Reported frequencies in one cohort/review summary: obsessions/compulsions 89%, anxiety 78%, emotional lability/depression 71%, sleep disorders 69%, attention deficit 63%, tics 62%, motor abnormalities 60%, school decline 50%, sensory abnormalities 50%, irritability/aggression 44%, urinary frequency 44%, hyperactivity 43%, eating disorders 40%, behavioral regression 40%, pain 38%. | HPO suggestions: Obsessive-compulsive behavior; Anxiety; Depressed mood; Sleep disturbance; Tic; Abnormality of movement; Attention-deficit/hyperactivity; Learning or school difficulty; Sensory disturbance; Irritability; Urinary frequency; Food refusal. | Observational/cohort summarized in review; moderate for phenotype spectrum, low-moderate for exact frequencies across settings (pqac-00000004, pqac-00000005) | DOI:10.2147/NDT.S362202 |
| Age / sex distribution | Mean onset reported around 7±2 years; peak onset 5–12 years; male predominance around 2:1 has been reported. | HPO: Childhood onset. | Review/consensus; moderate (pqac-00000002, pqac-00000005) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202 |
| Quality-of-life / functional burden | Symptoms can cause marked functional impairment, school decline, missed activities, and high caregiver burden; one sequencing paper states caregiver burden during first flare exceeds Alzheimer disease caregiving. | HPO: Impaired social/academic functioning; MAXO: supportive educational/psychological interventions. | Observational/review; moderate for substantial burden, low for cross-disease burden comparison generalizability (pqac-00000001, pqac-00000020) | DOI:10.1038/s41598-022-15279-3; NCT04609761 |
| Epidemiology | True incidence/prevalence remain uncertain; available reviews emphasize lack of rigorous epidemiology, though PANS may account for at least 1 in 20 pediatric-onset OCD cases in some estimates. | Not applicable. | Low-moderate; estimate-based and heterogeneous (pqac-00000000, pqac-00000004) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202 |
| Triggers: infectious | Infectious triggers reported include group A streptococcal infection, Mycoplasma pneumoniae, Borrelia burgdorferi, Staphylococcus aureus, and viral infections including Epstein-Barr, influenza, coxsackie, varicella, and SARS-CoV-2. PANDAS specifically requires temporal association with GAS. | CHEBI/NCBI Taxonomy not confidently assigned here. HPO: Postinfectious onset not available from provided evidence. | Review/consensus; moderate for association, low for proof of causality per pathogen (pqac-00000000, pqac-00000002, pqac-00000005) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202 |
| Triggers: noninfectious | Emotional stress and possible oxidative toxin exposure have been proposed as noninfectious triggers; these remain not established causal factors. | Not established. | Low/speculative (pqac-00000005) | DOI:10.2147/NDT.S362202 |
| Genetics | No single causal gene is established for PANS. Candidate ultra-rare variants were reported in 11 genes in 21/396 sequenced cases: PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHEK2/CHK2, GRIN2A, RAG1, GABRG2, SYNGAP1. These are candidate susceptibility genes, not diagnostic or causal markers. | HGNC gene symbols: PPM1D, SGCE, PLCG2, NLRC4, CACNA1B, SHANK3, CHEK2, GRIN2A, RAG1, GABRG2, SYNGAP1. | Human sequencing study; moderate for candidate-gene signal, low for causality/clinical validity (pqac-00000001) | DOI:10.1038/s41598-022-15279-3 |
| Family history / heritable predisposition | Increased family history of OCD, tics, and acute rheumatic fever has been reported; about 50% of cases may have pre-existing neurodevelopmental disorders, suggesting predisposition rather than monogenic inheritance. | HPO: Obsessive-compulsive behavior; Tic; Neurodevelopmental abnormality (general suggestion only). | Observational/review/consensus; low-moderate (pqac-00000000, pqac-00000001) | DOI:10.3389/fimmu.2024.1420663; DOI:10.1038/s41598-022-15279-3 |
| Pathophysiology: immune / autoimmune | Current leading model is infection- or inflammation-triggered neuroimmune dysregulation affecting brain circuits, but definitive autoimmune proof is lacking. Reported serum/CSF-associated markers include antibodies to dopamine D1/D2 receptors, lysoganglioside-GM1, β-tubulin, and elevated CaMKII activity; no biomarker is pathognomonic. | GO suggestions: immune response; inflammatory response; regulation of microglial activation; synaptic signaling. CL: microglial cell. | Review/consensus with inconsistent biomarker studies; low-moderate (pqac-00000000, pqac-00000005, pqac-00000006, pqac-00000007) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202 |
| Pathophysiology: candidate mechanisms | Sequencing and model-based interpretations suggest convergence on peripheral immune signaling, microglia, synaptic function, and blood-CSF/brain barrier vulnerability. | GO suggestions: synaptic signaling; regulation of cytokine production; blood-brain barrier maintenance. CL: microglial cell; neuron. | Mechanistic hypothesis from human genetics/review; low-moderate (pqac-00000001) | DOI:10.1038/s41598-022-15279-3 |
| Anatomy / neuroanatomy | Neuroimaging abnormalities have been reported in thalamus, basal ganglia, amygdala, and putamen; basal ganglia circuitry is a recurrent focus in PANS/PANDAS literature. | UBERON suggestions: brain; basal ganglion; thalamus; amygdala; putamen. | Review/consensus/observational; moderate for implicated regions, low for specificity (pqac-00000000, pqac-00000001, pqac-00000019, pqac-00000020) | DOI:10.3389/fimmu.2024.1420663; DOI:10.1038/s41598-022-15279-3; NCT02889016; NCT04609761 |
| Cell types / tissue level | Microglia are repeatedly implicated in proposed neuroinflammatory models; neuronal synapses are implicated by candidate genes. Specific pathogenic cell type is not established in human tissue. | CL: microglial cell; neuron. GO: microglial activation; synaptic signaling. | Mechanistic/model-informed inference; low-moderate (pqac-00000001) | DOI:10.1038/s41598-022-15279-3 |
| Diagnostics: overall approach | Diagnosis is clinical and exclusionary. Recommended workup includes physical, psychiatric, neurologic, and neuropsychological evaluation; targeted laboratory testing; and MRI/EEG/sleep evaluation, with CSF analysis reserved for severe or encephalitic presentations. | MAXO: MRI; EEG; cerebrospinal fluid examination; cognitive behavioral therapy assessment not an ontology certainty here. | Consensus/review; moderate (pqac-00000006, pqac-00000019, pqac-00000020) | DOI:10.2147/NDT.S362202; NCT02889016; NCT04609761 |
| Diagnostics: biomarkers | Infectious parameters have the strongest practical support when infection is suspected. D1/D2 receptor antibodies, lyso-GM1, β-tubulin, and CaMKII activity have been reported, but individual biomarkers lack sufficient sensitivity/specificity for diagnosis; no validated standalone biomarker exists. Cunningham panel utility remains uncertain. | No confident ontology IDs. | Moderate that no validated biomarker exists; low for specific assay clinical utility (pqac-00000000, pqac-00000006, pqac-00000022) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202; NCT02190292 |
| Differential diagnosis | Important exclusions include Sydenham chorea, autoimmune encephalitis/encephalitis, systemic lupus erythematosus, Tourette disorder, primary OCD, psychotic disorders, autism-related regression, and other neurologic/medical causes. | HPO/ontology not enumerated from evidence. | Consensus/guideline; moderate (pqac-00000003, pqac-00000017, pqac-00000021) | PMID 25325534; NCT04508530; NCT04609761 |
| Disease course | Often acute/subacute at onset with episodic, relapsing-remitting, or chronic progressive/disintegrative course; stabilization between flares may occur. | HPO: Episodic course; relapsing-remitting course (general suggestions). | Review/consensus; moderate (pqac-00000003, pqac-00000005, pqac-00000017) | DOI:10.2147/NDT.S362202; NCT04508530 |
| Prognosis / natural history | Long-term natural history is incompletely defined; some children improve substantially over time, but reviews caution that improvement may reflect fluctuating natural course rather than treatment effect alone. | Not applicable. | Low-moderate (pqac-00000012, pqac-00000014, pqac-00000022) | DOI:10.1093/pch/pxy145; NCT02190292 |
| First-line symptomatic treatment | CBT/ERP and SSRIs are commonly recommended first-line symptomatic treatments for OCD/anxiety symptoms; consensus advises not delaying psychiatric treatment while etiologic workup proceeds. Medication intolerance/sensitivity may be higher than in typical pediatric psychiatric populations. | MAXO suggestions: cognitive behavioral therapy; selective serotonin reuptake inhibitor therapy. | Consensus plus small studies/observational evidence; moderate for use, low-moderate for disease-specific efficacy (pqac-00000002, pqac-00000008, pqac-00000010, pqac-00000013, pqac-00000016) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202; NCT01617083 |
| Antibiotics | Antibiotics are recommended when active infection is identified. Evidence for disease-modifying benefit without active infection is mixed: a 4-week randomized azithromycin trial exists; long-term prophylaxis is not well supported. | MAXO suggestion: antibiotic therapy. | Moderate for treating documented infection; low-moderate for psychiatric symptom benefit beyond infection control (pqac-00000008, pqac-00000009, pqac-00000010, pqac-00000015, pqac-00000016) | NCT01617083; DOI:10.1093/pch/pxy145; DOI:10.2147/NDT.S362202 |
| NSAIDs / corticosteroids | NSAIDs and short corticosteroid courses are used in some protocols, especially mild to moderate inflammatory presentations, but evidence is limited and largely observational/consensus-based. | MAXO suggestions: nonsteroidal anti-inflammatory drug therapy; corticosteroid therapy. | Low-moderate (pqac-00000013, pqac-00000009) | DOI:10.3389/fimmu.2024.1420663; DOI:10.1093/pch/pxy145 |
| IVIG | IVIG is frequently used for moderate-to-severe or selected inflammatory PANS in expert protocols. Evidence includes older small controlled studies, observational/open-label studies, and recent/ongoing phase 2-3 trials; benefit remains debated and not definitively established. | MAXO suggestion: intravenous immunoglobulin therapy. | Moderate for clinical use; low-moderate for definitive efficacy due to heterogeneous and limited trials (pqac-00000008, pqac-00000009, pqac-00000012, pqac-00000017, pqac-00000020, pqac-00000021) | NCT04508530; NCT04609761; DOI:10.1093/pch/pxy145 |
| Plasma exchange | Therapeutic plasma exchange is reserved in expert guidance for extreme/life-threatening impairment; observational data suggest improvement in severe cases, but controlled evidence is limited. | MAXO suggestion: therapeutic plasma exchange. | Low-moderate (pqac-00000008, pqac-00000012) | DOI:10.2147/NDT.S362202; DOI:10.1093/pch/pxy145 |
| Rituximab / other immunomodulators | Rituximab is not routinely recommended for PANS and is generally reserved, if at all, for definite autoimmune encephalitis or highly selected refractory cases. Evidence in PANS specifically is minimal/not established. | MAXO suggestion: rituximab therapy. | Low/not established (pqac-00000008, pqac-00000013, pqac-00000018) | DOI:10.2147/NDT.S362202; NCT04508530 |
| Adverse effects / safety | IVIG adverse effects include nausea, myalgia, fever, chills/rigors, chest discomfort, hypotension, headache. Azithromycin trial protocols monitored hepatic toxicity and QTc prolongation. Psychotropics may require dose changes due to side effects in a high proportion of patients. | MAXO: adverse event monitoring; ECG monitoring; liver function monitoring. | Moderate for expected treatment-related adverse effects from protocols/reviews (pqac-00000008, pqac-00000010, pqac-00000016, pqac-00000020) | NCT01617083; NCT04609761; DOI:10.2147/NDT.S362202 |
| Prevention | No established primary prevention exists for PANS. Prevention of recurrent infectious triggers and prompt treatment of active infections are used pragmatically. A 2024 consensus mentions vitamin D prophylaxis suggestion, but this is not established standard-of-care. | MAXO suggestions: infection prevention/treatment; vitamin supplementation (vitamin D) only as low-confidence suggestion. | Low (pqac-00000002) | DOI:10.3389/fimmu.2024.1420663 |
| Real-world research implementation | Active real-world studies include biomarker discovery, longitudinal cohort characterization, and interventional trials: Stanford biomarker cohort (500 planned; NCT02889016), Scandinavian cohort (NCT02190292), azithromycin RCT (NCT01617083), IVIG open-label study (NCT04609761), and phase III Panzyga crossover trial (NCT04508530). | Not applicable. | Strong for existence of implementation/trials (pqac-00000015, pqac-00000017, pqac-00000019, pqac-00000020, pqac-00000022) | NCT02889016; NCT02190292; NCT01617083; NCT04609761; NCT04508530 |
| Evidence gaps / unknowns | Not established: single causal gene, validated diagnostic biomarker, prevalence/incidence, definitive autoimmune mechanism, standardized evidence-based treatment hierarchy, or disease-specific prevention strategy. | MONDO/OMIM/Orphanet IDs not established from available evidence. | Strong agreement across reviews/consensus that major gaps remain (pqac-00000000, pqac-00000006, pqac-00000007, pqac-00000014) | DOI:10.3389/fimmu.2024.1420663; DOI:10.2147/NDT.S362202; DOI:10.1093/pch/pxy145 |


*Table: This compact table summarizes the best-supported current findings for Pediatric Acute-onset Neuropsychiatric Syndrome across definition, phenotypes, triggers, candidate genetics, mechanisms, diagnostics, course, and treatment. It explicitly distinguishes established clinical criteria from areas that remain uncertain or unvalidated.*